URN:NBN:SI:doc-92M791BQ2022Martinc, Boštjandocuments/doc/9/URN_NBN_SI_doc-92M791BQ_001.pdfdocuments/doc/9/URN_NBN_SI_doc-92M791BQ_001.txt273articlestr. 115-1271406945312536-4316URN:NBN:SI:doc-92M791BQslvSlovensko farmacevtsko društvoFarmacevtski vestnikInCcardiovascular outcomesGLP-1 receptor agonistsledvični izidireceptorski agonisti GLP-1renal outcomesSGLT2 inhibitorsSladkorna bolezensladkorna bolezen tipa 2srčno-žilni iziditype 2 diabeteszaviralci SGLT2Novelties in the treatment of SGLT2 inhibitors and GLP-1 receptor agonistsNovosti pri zdravljenju z zaviralci SGLT2 in agonisti receptorjev GLP-1